Market closed

Cardiff Oncology/CRDF

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Cardiff Oncology

Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").

Ticker

CRDF
Trading on

Industry

Biotechnology

Employees

-

Cardiff Oncology Metrics

BasicAdvanced
$121M
Market cap
-
P/E ratio
-$0.92
EPS
1.94
Beta
-
Dividend rate
$121M
1.94
$6.42
$0.94
465K
4.971
4.853
2.178
3.518
-34.12%
-58.80%
174.825
2.26
2.26
-3.581
61.41%
2.33%
18.86%
10.29%

What the Analysts think about Cardiff Oncology

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Cardiff Oncology stock.

Cardiff Oncology Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Cardiff Oncology Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy CRDF

$

Sign up or log in to buy
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Cardiff Oncology stock?

Cardiff Oncology (CRDF) has a market cap of $121M as of October 06, 2024.

What is the P/E ratio for Cardiff Oncology stock?

The price to earnings (P/E) ratio for Cardiff Oncology (CRDF) stock is 0 as of October 06, 2024.

Does Cardiff Oncology stock pay dividends?

No, Cardiff Oncology (CRDF) stock does not pay dividends to its shareholders as of October 06, 2024.

When is the next Cardiff Oncology dividend payment date?

Cardiff Oncology (CRDF) stock does not pay dividends to its shareholders.

What is the beta indicator for Cardiff Oncology?

Cardiff Oncology (CRDF) has a beta rating of 1.94. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.